- Home
- NRIX vs NGL Comparison
NRIX vs NGL Comparison
Compare NRIX & NGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- NGL
- Stock Information
- Founded
- NRIX 2009
- NGL 1940
- Country
- NRIX United States
- NGL United States
- Employees
- NRIX N/A
- NGL N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- NGL Natural Gas Distribution
- Sector
- NRIX Health Care
- NGL Utilities
- Exchange
- NRIX Nasdaq
- NGL Nasdaq
- Market Cap
- NRIX 750.4M
- NGL 751.7M
- IPO Year
- NRIX 2020
- NGL 2011
- Fundamental
- Price
- NRIX $12.83
- NGL $9.85
- Analyst Decision
- NRIX Strong Buy
- NGL
- Analyst Count
- NRIX 14
- NGL 0
- Target Price
- NRIX $26.29
- NGL N/A
- AVG Volume (30 Days)
- NRIX 2.0M
- NGL 470.5K
- Earning Date
- NRIX 10-09-2025
- NGL 11-04-2025
- Dividend Yield
- NRIX N/A
- NGL N/A
- EPS Growth
- NRIX N/A
- NGL N/A
- EPS
- NRIX N/A
- NGL N/A
- Revenue
- NRIX $83,687,000.00
- NGL $3,250,313,000.00
- Revenue This Year
- NRIX $58.48
- NGL N/A
- Revenue Next Year
- NRIX N/A
- NGL N/A
- P/E Ratio
- NRIX N/A
- NGL N/A
- Revenue Growth
- NRIX 48.32
- NGL 46.95
- 52 Week Low
- NRIX $8.18
- NGL $2.64
- 52 Week High
- NRIX $27.53
- NGL $10.29
- Technical
- Relative Strength Index (RSI)
- NRIX 61.69
- NGL 80.26
- Support Level
- NRIX $12.01
- NGL $6.30
- Resistance Level
- NRIX $13.03
- NGL $6.50
- Average True Range (ATR)
- NRIX 0.86
- NGL 0.49
- MACD
- NRIX -0.03
- NGL 0.27
- Stochastic Oscillator
- NRIX 77.21
- NGL 90.32
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About NGL NGL ENERGY PARTNERS LP Common Units representing Limited Partner Interests
NGL Energy Partners LP is a USA-based firm that owns and operates a vertically integrated energy business. The company's operating segments include Crude Oil Logistics, Water Solutions, and Liquids Logistics. It operates crude oil Logistics, owns pipeline injection stations, and offers services for the treatment and disposal of wastewater generated from crude oil and natural gas production, as well as for the disposal of solids, such as tank bottoms and drilling fluids. The firm also supplies natural gas liquids to retailers, wholesalers, refiners, and petrochemical plants and sells propane and distillates.